Treatment: antithyroid drugs
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Treatment: antithyroid drugs
Laboratory tests before starting treatment
- FBC
- TSH
- Free T4 (or free T3 in T3 hyperthyroidism)
- ASTWarning sign of hepatitis; the SFE and the GRT also suggest a check before initiation and after 3 or 4 weeks.
- ALTWarning sign of hepatitis; the SFE and the GRT also suggest a check before initiation and after 3 or 4 weeks.
- GGTWarning sign of hepatitis; the SFE and the GRT also suggest a check before initiation and after 3 or 4 weeks.
- Alkaline phosphataseWarning sign of hepatitis; the SFE and the GRT also suggest a check before initiation and after 3 or 4 weeks.
FBC every week for the first 6 weeks
- FBC (one a week, 6 in total)
- If fever, sore throat or sign of infection: stop the antithyroid drug and do an urgent FBC.
Laboratory tests between day 21 and day 42
- Free T4 (or free T3 in T3 hyperthyroidism)
- Free T3 (in addition to free T4)if needednon-French guidelineUS and UK practice: the American Thyroid Association measures free T4 and T3 from 2 to 6 weeks of treatment, because free T4 may normalise while T3 remains high [2]; NICE measures TSH, free T4 and free T3 every 6 weeks until TSH normalises [3]. HAS asks for free T3 only if it was initially abnormal [4].
- ASTif neededWarning sign of liver injury (jaundice, pale stools, dark urine, abdominal pain, pruritus): liver function tests without waiting [4,5]. No consensus on routine monitoring [4,6]; clinical hepatitis or transaminases > 3 times normal require stopping the antithyroid drug [6].
- ALTif neededWarning sign of liver injury (jaundice, pale stools, dark urine, abdominal pain, pruritus): liver function tests without waiting [4,5]. No consensus on routine monitoring [4,6]; clinical hepatitis or transaminases > 3 times normal require stopping the antithyroid drug [6].
- GGTif neededWarning sign of liver injury (jaundice, pale stools, dark urine, abdominal pain, pruritus): liver function tests without waiting [4,5]. No consensus on routine monitoring [4,6]; clinical hepatitis or transaminases > 3 times normal require stopping the antithyroid drug [6].
- Alkaline phosphataseif neededWarning sign of liver injury (jaundice, pale stools, dark urine, abdominal pain, pruritus): liver function tests without waiting [4,5]. No consensus on routine monitoring [4,6]; clinical hepatitis or transaminases > 3 times normal require stopping the antithyroid drug [6].
Laboratory tests at day 60 (M2)
- Free T4 (or free T3 in T3 hyperthyroidism)
- Repeat every 3-6 weeks until free T4 normalises
TSH every 2 to 4 months thereafter
- TSH
Do not order
Before and after stopping treatment (Graves' disease)
Before the decision to stop (after 12 to 18 months of treatment)
- TSH receptor antibodies (TRAb)
- TSH
After stopping: at 6-8 weeks, 3 months, 6 months and 12 months
Do not order
Sources (13)
- Assurance maladie. Open Medic 2024, base « nombre de consommants » par code ATC5 (fichier NB_2024_atc5), open-data-assurance-maladie.ameli.fr, téléchargé le 23/10/2026, relu le 24/10/2026.
- Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
- National Institute for Health and Care Excellence (NICE). Thyroid disease: assessment and management. NICE guideline NG145, publiée le 20 novembre 2019, mise à jour le 12 octobre 2023 (recommandations 1.6.21 et 1.7.9 à 1.7.11, et leur justification).
- Haute Autorité de santé. Prise en charge des hyperthyroïdies chez l’adulte (population générale). Recommandation de bonne pratique, validée par le Collège le 15 décembre 2022 (texte des recommandations et fiche de synthèse).
- Résumé des caractéristiques du produit NEO-MERCAZOLE 5 mg, comprimé (carbimazole), rubriques 4.2 et 4.4 (ANSM, mis à jour le 07/10/2025). Base de données publique des médicaments.
- Corvilain B, Hamy A, Brunaud L, Borson-Chazot F, Orgiazzi J, Bensalem Hachmi L, Semrouni M, Rodien P, Lussey-Lepoutre C. Treatment of adult Graves’ disease. Ann Endocrinol (Paris). 2018;79(6):618-635.
- Résumé des caractéristiques du produit BASDENE 25 mg, comprimé (benzylthiouracile), rubriques 4.2 et 4.4 (ANSM, mis à jour le 06/02/2025). Base de données publique des médicaments.
- Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.
- Résumé des caractéristiques du produit THYROZOL 10 mg, comprimé pelliculé sécable (thiamazole), rubrique 4.4 (ANSM, mis à jour le 11/04/2023). Base de données publique des médicaments.
- Centre belge d’information pharmacothérapeutique (CBIP). Répertoire commenté des médicaments, chapitre 5.3.3 « Antithyroïdiens » (version du 22/10/2026).
- Thérapeutique Knight inc. Monographie de produit : TAPAZOLE (méthimazole), comprimés de 5 et 10 mg. Santé Canada, révision du 19 décembre 2025.
- Spaulding SW. Are biweekly granulocyte counts effective in forecasting the onset of agranulocytosis in patients with Graves’ disease who are receiving antithyroid drugs? Clin Thyroidol. 2013;25(11):244-246 (commentaire de Nakamura H et al., J Clin Endocrinol Metab 2013, doi:10.1210/jc.2013-2569).
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1208 (TSH), 1209 (T3L + T4L), 1212 (TSH + T4L + T3L), 1488 (anticorps antirécepteurs de la TSH).